BioSpace News Archive

Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidate Agreement valued at approximately $87 million GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it will deploy its molecule-to-market contract development and manufacturing (CDMO) services to support the manufacturing of AstraZeneca’s vaccine candidate for

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that the Medicines and Healthcare products Regulatory Agency (MHRA; the UK equivalent of the FDA) has given approval to i

Regence today announced a new partnership with Healthmap Solutions—a growing national Population Health Management company with a flagship Kidney Health Management (KHM) program—to improve care and outcomes for Regence members with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD).

Next Generation Closed Loop Insulin Pump System Features Auto-Correction Algorithm and Bluetooth Connectivity

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced the pricing of its previously announced underwritten public offering. Mustang is offering 10,769,231 shares of its common stock, par value $0.0001 per share, at a price to the

SenesTech, Inc., a developer of proprietary technologies for managing animal pest populations through fertility control, encourages businesses and pest management professionals to deploy ContraPest® in their integrated pest management programs to enhance rat control as communities begin to reopen.

Welldoc® , revolutionizing digital health with the first FDA-cleared Software as a Medical Device (SaMD) for diabetes, today announced the expansion of an agreement with Mass General Brigham (formerly Partners HealthCare). After conducting a 2-year program of Quality Improvement (QI) research with the Ambulatory Practice of the Future

Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that Timothy P. Moran, Chief Executive Officer of Motus GI, will present at the Virtual Investor Fireside Chat Series on Monday, June 15, 2020,

Using the Abiprot TM antibody discovery platform, a team of researchers has identified a potentially important epitope in SARS-CoV-2 that may facilitate generation of neutralizing antibodies to treat Covid-19 patients. The epitope is part of the spike protein which mediates the virus entry into cells. It was identified in a pilo

Exeltis USA, Inc, a division of Insud Pharma, today released a physician and patient communication letter announcing a recent publication in Drugs of Today 2020 that highlights the Slynd safety data and the efficacy of drospirenone to inhibit ovulation, reinforcing the features and benefits of Slynd